TYRA MEXC RealStocks
Own real TYRA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 07:18:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Tyra Biosciences, Inc. (TYRA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $19.62, with a market capitalization of $1.35B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $15.94 to $40.65. This page covers its latest market performance, valuation, price trends and company information.
$1.35B | |
$19.50 | |
$20.22 | |
$19.34 | |
$19.57 | |
339.89K | |
861.07K | |
-- | |
$40.65 | |
$15.94 | |
-- | |
2026-09-30 |
Tyra Biosciences, Inc. (TYRA) last closed at $19.62 as of 2026-11-19 00:31:00, up 0.33% ($0.07) from the previous close of $19.57.
During the latest regular trading session, TYRA traded between $19.34 and $20.22, with a volume of 339.89K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Tyra Biosciences, Inc. (TYRA) moved from $21.00 to $19.62, representing a decline of 6.57% ($1.38).
The stock traded between $19.26 and $22.58 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 646.38 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 14.9%
TYRA is currently trading at $19.62, placing it 14.9% of the way from its 52-week low of $15.94 to its 52-week high of $40.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 87 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tyra Biosciences, Inc. (TYRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TYRA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TYRA shares and USD.
TYRA Shares to USD
1.00 TYRA shares = 19.62 USD
Calculations are estimates based on the latest available price and are for reference only.